SRR12475123
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- P53_PATHWAY+0.260
- NOTCH_SIGNALING+0.190
- OXIDATIVE_PHOSPHORYLATION+0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.180
- XENOBIOTIC_METABOLISM+0.180
- HEME_METABOLISM+0.130
- PEROXISOME+0.120
- ESTROGEN_RESPONSE_EARLY+0.110
- ESTROGEN_RESPONSE_LATE+0.090
- ADIPOGENESIS+0.080
Top 10 suppressed
- E2F_TARGETS-0.550
- G2M_CHECKPOINT-0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- MTORC1_SIGNALING-0.380
- MYC_TARGETS_V1-0.360
- ANGIOGENESIS-0.350
- MITOTIC_SPINDLE-0.330
- HEDGEHOG_SIGNALING-0.310
- SPERMATOGENESIS-0.280
- COMPLEMENT-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-NJ-A7XG-01A-12R-A39D-07 | — | cohortA1 | 0.817 |
| 2 | 308a5759-8930-433f-8d11-4c3da6ed0e29 | — | — | 0.804 |
| 3 | MDT-AP-0757 | Med | Medulloblastoma | 0.787 |
| 4 | TCGA-YF-AA3L-01A-11R-A38B-07 | — | — | 0.777 |
| 5 | s_150203_5a | EPN | Posterior Fossa EPN | 0.777 |
| 6 | SRR10899977 | — | — | 0.775 |
| 7 | TCGA-DK-A6B0-01A-11R-A31N-07 | — | — | 0.774 |
| 8 | TCGA-E2-A1B4-01A-11R-A12P-07 | — | B | 0.774 |
| 9 | TCGA-E2-A2P6-01A-11R-A19W-07 | — | B | 0.772 |
| 10 | R84 | — | — | 0.772 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.050 | Inavolisib | — uncovered |
| HYPOXIA | 0.020 | Idelalisib | — uncovered |